natgillin/translations-raw huggingface dataset:
Entyvio must not be used in people with active serious infections such as tuberculosis, sepsis (infection in the blood), listeriosis (infection with bacteria called Listeria) or opportunistic infections (those seen in patients with a weakened immune system) such as progressive multifocal leukoencephalopathy (PML, a rare brain infection that usually leads to severe disability or death).
Zdravilo Entyvio se ne sme uporabljati pri osebah z aktivnimi resnimi okužbami, kot so tuberkuloza, sepsa (okužba krvi), listerioza (okužba z bakterijo, imenovano Listeria) ali oportunistične okužbe (takšne, ki se pojavijo pri bolnikih z oslabljenim imunskim sistemom), kot je progresivna multifokalna levkoencefalopatija (PML, tj. redka okužba možganov, ki običajno povzroči hudo invalidnost ali smrt).
What are the risks associated with Entyvio?
Kakšna tveganja so povezana z zdravilom Entyvio?
For more information about treatment with Entyvio, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Entyvio preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Patients received either Entyvio or placebo (a dummy treatment) and the main measure of effectiveness was the proportion of patients whose symptoms improved after 6 weeks of treatment.
Bolniki so prejemali bodisi zdravilo Entyvio bodisi placebo (zdravilo brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bilo delež bolnikov, pri katerih so se po 6 tednih zdravljenja simptomi izboljšali.
Entyvio is produced by a method known as ‘recombinant DNA technology'; it is made by cells into which a gene (DNA) has been introduced that makes them able to produce vedolizumab.
Zdravilo Entyvio se pridobiva z metodo, imenovano „tehnologija rekombinantne DNA“: izdelajo ga celice, v katere so vstavili gen (DNA), s pomočjo katerega lahko tvorijo vedolizumab.
Entyvio was shown to be more effective than placebo: 47% (106 out of 225) of patients who received Entyvio showed an improvement in symptoms, compared with 26% (38 out of 149) of patients who received placebo.
Zdravilo Entyvio se je izkazalo za učinkovitejše od placeba: izboljšanje simptomov so opazili pri 47 % (106 od 225) bolnikov, ki so prejemali zdravilo Entyvio, v primerjavi s 26 % (38 od 149) bolnikov, ki so prejemali placebo.
It can only be obtained with a prescription and treatment should be started and supervised by a specialist who has experience in the diagnosis and treatment of ulcerative colitis or Crohn's disease.
Izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem ulceroznega kolitisa ali Crohnove bolezni.
What benefits of Entyvio have been shown in studies?
Kakšne koristi je zdravilo Entyvio izkazalo v študijah?
The most common side effects with Entyvio (which may affect more than 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat such as a cold), headache and arthralgia (joint pain).
Najpogostejši neželeni učinki zdravila Entyvio (ki se lahko pojavijo pri več kot 1 osebi od 10) so nazofaringitis (vnetje nosu in žrela, kot je na primer prehlad), glavobol in artralgija (bolečine v sklepih).
By blocking alfa-4-beta-7 integrin, vedolizumab reduces the inflammation in the gut and the symptoms of these diseases.
Vedolizumab z zaviranjem integrina alfa-4-beta-7 zmanjša vnetje v črevesju in simptome teh bolezni.
In Crohn's disease, the CHMP considered that although the time required for improvement of symptoms may be longer and the size of the effect limited when compared with anti-TNF-alfa therapy, Entyvio still offers a benefit for patients because of its different mechanism of action and safety profile.
Glede Crohnove bolezni je odbor CHMP menil, da je sicer čas, potreben za izboljšanje simptomov, lahko daljši, obseg učinka pa omejen v primerjavi z zdravljenjem z zaviralci TNF-alfa, vendar ima zdravilo Entyvio zaradi drugačnega mehanizma delovanja ter varnostnega profila kljub temu koristi za bolnike.
It is used to treat adult patients with ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut) or Crohn's disease (a disease causing inflammation of the digestive tract).
Uporablja se za zdravljenje odraslih bolnikov z ulceroznim kolitisom (boleznijo, ki povzroča vnetje in razjede na črevesni sluznici) ali Crohnovo boleznijo (boleznijo, ki povzroča vnetje prebavnega trakta).
Entyvio is a medicine that contains the active substance vedolizumab.
Entyvio je zdravilo, ki vsebuje zdravilno učinkovino vedolizumab.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Entyvio, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Entyvio in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
In one main study in adult patients with moderate to severe active Crohn's disease in whom conventional therapy or TNF-alfa antagonists were ineffective or could not be tolerated, 15% (32 out of 220) of patients receiving Entyvio showed improved symptoms after 6 weeks of treatment, compared with 7% (10 out of 148) of patients on placebo.
V eni glavni študiji pri odraslih bolnikih z zmerno do močno aktivno Crohnovo boleznijo, pri katerih konvencionalno zdravljenje ali zdravljenje z zaviralci TNF-alfa ni bilo učinkovito ali pa ga niso prenašali, so izboljšanje simptomov po 6 tednih opazili pri 15 % (32 od 220) bolnikov, ki so prejemali zdravilo Entyvio, v primerjavi s 7 % (10 od 148) bolnikov, ki so prejemali placebo.
Similarly, in this study the maintenance of the effect up to 52 weeks with Entyvio was more effective than with placebo.
Podobno je bilo v tej študiji vzdrževanje učinka zdravila Entyvio v obdobju 52 tednov uspešnejše kot pri placebu.
In ulcerative colitis, the Committee considered that the benefit of Entyvio has been clearly demonstrated, which is relevant for patients who do not respond to TNF-alfa therapy.
Odbor je menil, da je bila pri ulceroznem kolitisu korist zdravila Entyvio nedvomno dokazana, kar je pomembno za bolnike, ki se ne odzivajo na zdravljenje z zaviralci TNF-alfa.
For practical information about using Entyvio, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Entyvio naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
In addition, the study also showed that Entyvio maintained the effect up to 52 weeks more effectively than placebo.
Poleg tega je študija pokazala, da je zdravilo Entyvio uspešneje vzdrževalo učinek v obdobju 52 tednov kot placebo.
Vedolizumab is used to treat moderate to severe active disease when conventional therapy or medicines called TNF-alfa antagonists are ineffective, no longer effective, or cannot be tolerated by the patient.
Vedolizumab se uporablja za zdravljenje zmerno do močno aktivne bolezni, kadar konvencionalno zdravljenje ali zdravljenje z zdravili, imenovanimi zaviralci tumorje nekrotizirajočega faktorja alfa (TNF-alfa), ni učinkovito, ni več učinkovito ali pa ga bolnik ne prenaša.
For the full list of all side effects reported with Entyvio, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Entyvio, glejte navodilo za uporabo.
In ulcerative colitis, Entyvio has been investigated in a main study in patients with moderate to severe active disease in whom conventional therapy or TNF-alfa antagonists were ineffective or could not be tolerated.
Zdravilo Entyvio so pri ulceroznem kolitisu proučili v glavni študiji pri bolnikih z zmerno do močno aktivno boleznijo, pri katerih konvencionalno zdravljenje ali zdravljenje z zaviralci TNF-alfa ni bilo učinkovito ali pa ga niso prenašali.
All patients are monitored for any reactions during the infusion and for at least one to two hours after the end of the infusion.
Med infundiranjem in še najmanj eno do dve uri po njem je treba preverjati, ali so se pri bolniku pojavile kakršne koli reakcije.
The active substance in Entyvio, vedolizumab, is a monoclonal antibody.
Zdravilna učinkovina v zdravilu Entyvio, vedolizumab, je monoklonsko protitelo.
Entyvio is available as a powder to be made up into a solution for infusion (drip) into a vein.
Zdravilo Entyvio je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalno infuzijo) v veno.
How is Entyvio used?
Kako se zdravilo Entyvio uporablja?
How does Entyvio work?
Kako zdravilo Entyvio deluje?
The European Commission issued a decision on 2 September 2011.
Evropska komisija je odločbo izdala 2. septembra 2011.
The use in children was further clarified.
Natančneje je bila pojasnjena tudi uporaba pri otrocih.
Diflucan is authorised in the EU via national procedures.
Zdravilo Diflucan je v EU odobreno z nacionalnimi postopki.
Why was Diflucan reviewed?
Zakaj je bilo zdravilo Diflucan pregledano?
The CHMP harmonised the dosing recommendations for the various indications to be in line with international guidelines.
CHMP je uskladil priporočila za odmerjanje za različne indikacije, tako da so usklajena z mednarodnimi smernicami.
The European Medicines Agency has completed a review of Diflucan.
Evropska agencija za zdravila je zaključila pregled zdravila Diflucan.
The Committee harmonised the wording on the use of the medicine for these conditions, specifying when it is to be used for treatment and prophylaxis (prevention) and introducing restrictions for certain indications.
Odbor je uskladil besedilo za uporabo zdravila pri teh boleznih in opredelil, kdaj je treba zdravilo uporabljati za zdravljenje in profilakso (preprečevanje), ter uvedel omejitve za nekatere indikacije.
On 18 February 2010, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Diflucan in the EU.
Evropska komisija je 18. februarja 2010 zadevo napotila na CHMP, da bi uskladila dovoljenja za promet z zdravilom Diflucan v EU.
Diflucan is an antifungal medicine that belongs to the triazoles group.
Diflucan je protiglivično zdravilo, ki spada v skupino triazolov.
It contains the active substance fluconazole.
Vsebuje zdravilno učinkovino flukonazol.
Diflucan is also available in the EU under other trade names: Fluconazole, Fungustatin, Fungata, Triflucan.
Zdravilo Diflucan je v EU na voljo tudi pod drugimi tržnimi imeni: Fluconazole, Fungustatin, Fungata, Triflucan.
Medicines known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine and erythromycin should also not be given to patients receiving Diflucan.
Zdravila, za katera je znano, da podaljšujejo interval QT in ki se presnavljajo prek citokroma P450 (CYP) 3A4, kot so cisaprid, astemizol, pimozid, kinidin in eritromicin, se prav tako ne smejo dajati bolnikom, ki jemljejo zdravilo Diflucan.
Diflucan works by preventing the formation of ergosterol, which is an important part of fungal cell walls.
Zdravilo Diflucan deluje tako, da preprečuje nastajanje ergosterola, ki je pomemben del glivičnih celičnih sten.
Other sections harmonised by the CHMP include sections on special warnings, side effects, interactions, pharmacological properties and quality.
Druga poglavja, ki jih je uskladil CHMP, so poglavje s posebnimi opozorili, o neželenih učinkih, medsebojnem delovanju, farmakoloških lastnostih ter kakovosti zdravila.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Diflucan in the European Union (EU).
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji je zaključil, da je treba v Evropski uniji (EU) uskladiti podatke o predpisovanju zdravila Diflucan.
Terfenadine must also not be used in patients receiving Diflucan at multiple doses of 400 mg per day or higher.
Pri bolnikih, ki jemljejo zdravilo Diflucan z večkratnimi odmerki v količini 400 mg na dan ali več, se prav tako ne sme uporabljati terfenadin.
The CHMP agreed that Diflucan should not be used in patients who are hypersensitive (allergic) to the active substance, to related azole substances, or to any of other ingredient of the medicine.
CHMP je potrdil, da se zdravilo Diflucan ne sme uporabljati pri bolnikih, ki so preobčutljivi za (alergični na) zdravilno učinkovino, na sorodne azolne snovi ali katero koli drugo sestavino zdravila.
The CHMP agreed that Diflucan can be used for the following conditions: mucosal and invasive candidiasis, genital candidiasis (trush), crypotococcal meningitis, dermatomycosis, coccidiodomycosis and onychomycosis.
CHMP je potrdil, da se zdravilo Diflucan lahko uporablja za naslednje bolezni: mukozna in invazivna kandidiaza, genitalna kandidiaza (sor), kriptokokni meningitis, dermatomikoze, kokcidiodomikoze in onihomikoze.
What is Diflucan?
Kaj je zdravilo Diflucan?
Diflucan is used to treat various fungal infections, including candidiasis (thrush) and fungus in the nails.
Zdravilo Diflucan se uporablja za zdravljenje različnih glivičnih okužb, vključno s kandidiazo (sor) in nohtnimi glivicami.
Diflucan was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila za uporabo v humani medicini CMD(h) je ugotovila, da je za zdravilo Diflucan potrebno usklajevanje.
As a result of the following weaknesses identified with this study the results could not be accepted:
Kot posledica naslednjih slabosti, ugotovljenih pri tej študiji, rezultatov niso mogli sprejeti:
• The possibility of release into the environment has not been investigated.
• možnost sproščanja v okolje ni bila raziskana.
In the first phase the DT50 was calculated to be 4 hours, while it was 12 hours in the second phase.
V prvi fazi je bil izračunani DT50 4 ure, medtem ko je bil v drugi fazi 12 ur.
However at the end of the study (27 days), 64% of the dose formed non-extractable residues.
Vendar pa so ob koncu študije (27 dni) 64 % odmerka sestavljali ostanki, ki jih ni bilo mogoče ekstrahirati.
The DT50 was further recalculated in accordance with a biphasic model.
DT50 so ponovno izračunali v skladu z bifaznim modelom.
Res Vet Sci. 1980 May;28(3):267-74.
Res Vet Sci. 1980 maj;28(3):267-74.
Member State Applicant/Marketing Authorisation Holder
Država članica Predlagatelj/imetnik dovoljenja za promet z zdravilom
When such specific information is not available the default values given in the guideline are applied.
Kadar tovrstne specifične informacije niso na voljo, se uporabijo privzete vrednosti, podane v smernici.
The CVMP therefore considers that the objections raised by Germany and The Netherlands should not prevent the granting of a Marketing Authorisation.
CVMP zato meni, da ugovori Nemčije in Nizozemske ne smejo preprečiti odobritve dovoljenja za promet z zdravilom.
It is assumed that veterinary medicinal products with limited use and limited environmental exposure will have a limited impact on the environment.
Predpostavlja se, da bodo imela zdravila za uporabo v veterinarski medicini, ki imajo omejeno uporabo in omejeno izpostavljenost okolju, omejen vpliv na okolje.
The incidence takes into account the number of ill animals at the start of the study and all additional animals becoming ill during the observation period.
Pri pojavnosti se upoštevajo število bolnih živali na začetku študije in vse dodatne živali, ki zbolijo v opazovanem obdobju.
The guidance document also allows for the use of alternative values if appropriately justified.
Smernica prav tako dovoljuje uporabo drugih vrednosti, če so te primerno utemeljene.
• The nature and the biological activity of bound residues is not known,
• vrsta in biološka aktivnost vezanih ostankov ni znana,
10000 = Area of 1 hectare [m2 .ha-1]
10000 = Površina 1 hektar [m2 .ha-1]
Therefore it was concluded that all extractable degradation products would represent less than 5% of the dose by day 27.
Zato so zaključili, da bodo vsi razkrojni produkti, ki jih je mogoče ekstrahirati, do 27. dne predstavljali manj kot 5 % odmerka.
OVERALL SUMMARY OF THE SCIENTIFIC CONCLUSIONS 1.
SPLOŠNI POVZETEK ZNANSTVENIH ZAKLJUČKOV
The environmental risk assessment is carried out as a two Phase process.
Ocena tveganja za okolje se izvede v dveh fazah.
The valid Summary of Product Characteristics, Labelling and Package Leaflet are the final versions achieved during the Coordination Group procedure with the following amendment:
Veljavni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so končne različice, sprejete med postopkom koordinacijske skupine, z naslednjim dopolnilom:
The proportion of animals in the herd which are treated may be available from information in the dossier such as field trial data or from the scientific literature.
Delež zdravljenih živali v čredi je lahko na voljo iz informacij v dokumentaciji, kot so podatki terenskih preskušanj ali podatki iz znanstvene literature.
The data available on BRD incidence within herds in the EU can be summarized as follows:
Podatke, ki so na voljo o pojavnosti respiratorne bolezni goveda znotraj čred v EU, lahko povzamemo na naslednji način:
All other potential degradation products of florfenicol were below the LOD by day 2.
Vsi drugi možni razkrojni produkti florfenikola so bili do 2. dne pod mejo zaznavnosti.
The CVMP reviewed bibliographical information on the incidence of BRD in several EU countries and on the percentage of animals that have been treated therapeutically and preventatively.
CVMP je pregledal bibliografske podatke o pojavnosti respiratorne bolezni goveda v več državah EU in o odstotku živali, ki so jih zdravili terapevtsko in preventivno.
The incidence rate observed by Martin et al, 2007 was refined to include the animals presenting clinical signs of BRD before the study, with the result that the incidence was increased to 37.7%.
Delež pojavnosti, kot ga je ugotovil Martin et al, 2007, so izpopolnili tako, da so vključili živali, ki so pred študijo kazale klinične znake respiratorne bolezni goveda, zaradi česar se je pojavnost povečala na 37,7 %.
United Kingdom Gosmore Ltd 9 Pitch and Pay Lane Sneyd Park,
Združeno kraljestvo Gosmore Ltd 9 Pitch and Pay Lane Sneyd Park,
In relation to the proportion of a herd to be treated, it was noted that disease incidence and subsequent therapy are difficult to dissociate.
V zvezi z deležem črede, ki bo zdravljen, so opazili, da je pojavnost bolezni in posledično zdravljenje težko ločiti.
The CVMP considers that the therapeutic indication as currently authorised in the Reference Member State does not make the limitations of the approved use clear as the existing wording could be interpreted as allowing use of the product for preventative and therapeutic treatment of all diseases caused by florfenicol susceptible bacteria.
CVMP meni, da terapevtska indikacija, kot je trenutno odobrena v referenčni državi članici, ne določa jasno omejitve odobrene uporabe, saj bi obstoječe besedilo lahko razlagali, kot da dovoljuje uporabo zdravila za preventivno in terapevtsko zdravljenje vseh bolezni, ki jih povzročajo za florfenikol občutljive bakterije.
2.3 Degradation of residues in manure
2.3 Razkroj ostankov v gnoju
= Depth of penetration into soil [m]
= Globina prodiranja v tla [m]
From the above data it can be concluded that incidence of BRD within herds in the EU is generally below 50%.
Iz zgoraj navedenih podatkov lahko zaključimo, da je pojavnost respiratorne bolezni goveda znotraj čred v EU na splošno nižja od 50 %.
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE VETERINARY MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER/APPLICANT IN THE MEMBER STATES
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI, ŽIVALSKIH VRST, POTI UPORABE ZDRAVILA, IMETNIKOV/PREDLAGATELJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
In Phase I the calculation of the initial PEC in soil is performed when more than a “small number of animals” are treated.
V I. fazi se izračuna začetna vrednost PKO v tleh, kadar se zdravi več kot „manjše število živali“.
• The nature of the binding is not known,
• vrsta vezave ni znana,
If appropriate, the assessment proceeds to the second phase where the fate and effects of the product are determined and a risk assessment for the relevant environmental compartment is carried out.
Kadar je to potrebno, se ocenjevanje nadaljuje z drugo fazo, pri kateri se določita obnašanje in vpliv zdravila ter se izvede ocena tveganja za ustrezni del okolja.
Considering the totality of the data the CVMP considered that this figure represents a conservative estimate of the overall BRD incidence rate within herds in the EU.
Ob upoštevanju popolnosti podatkov je CVMP menil, da predstavlja to število konservativno oceno celotne pojavnosti respiratorne bolezni govedi znotraj čred v EU.
2.1 Incidence of BRD (Bovine Respiratory Disease)
2.1 Pojavnost respiratorne bolezni goveda
PECsoil initial = Predicted Environmental Concentration in soil [μg.kg-1] D
PKOtla začetni = Predvidena okoljska koncentracija v tleh [μg.kg-1] D
Phase I identifies veterinary medicinal products that require a more extensive environmental risk assessment.
V I. fazi se opredelijo zdravila za uporabo v veterinarski medicini, ki zahtevajo obsežnejšo oceno tveganja za okolje.
Because Fenflor 300 mg/ml solution for injection for cattle is indicated for treatment only (i.e. it is indicated only for use in clinically ill animals not for preventative use) it was considered that, in this case, it was appropriate to use the disease incidence within the herd as the proportion of animals treated.
Ker je zdravilo Fenflor 300 mg/ml raztopina za injiciranje za govedo indicirano le za zdravljenje (tj. indicirano je le za uporabo pri klinično bolnih živalih in ne za preventivno uporabo), se je ugotovilo, da je v tem primeru primerno uporabiti pojavnost bolezni znotraj črede kot delež živali, ki so zdravljene.
= Nitrogen produced in one year per place [kg.N.
= Proizvodnja dušika v enem letu na mesto [kg.N.
= Daily dose of the active ingredient [mg.kgbw
= Dnevni odmerek zdravilne učinkovine [mg.kgtm
Using the value of 38% for the proportion of treated animals in a herd, a maximum PECsoil value of 88.6 μg/kg was calculated.
Z uporabo vrednosti 38 % kot deleža zdravljenih živali v čredi je bila izračunana najvišja vrednost PKOtla 88,6 μg/kg.
= Housing factor either 1 for animals housed throughout the year or 0.5 for animals housed for only 6 months (see Table 3 of the guideline) = Conversion factor [1000 μg.mg-1]
= Koeficient nastanitve je 1 za živali, ki so nastanjene celo leto, ali 0,5 za živali, ki so nastanjene le po 6 mesecev (glejte razpredelnico 3 v smernici) = Faktor menjave [1000 μg.mg-1]
During the mutual recognition procedure concerns were raised that Fenflor 300 mg/ml solution for injection for cattle may present a potential serious risk to the environment.
Med postopkom z medsebojnim priznavanjem so se pojavili zadržki, da lahko zdravilo Fenflor, 300 mg/ml raztopina za injiciranje, za pri uporabio pri govedu pomeni možno resno tveganje za okolje.
The Marketing Authorisation Holder provided a study to demonstrate that florfenicol degrades rapidly, with a DT50 of 14 hours (calculated using the Arrhenius equation to extrapolate from a DT50 of 5 hours measured at 20°C rather than at 10°C, as recommended in the CVMP guideline).
Imetnik dovoljenja za promet z zdravilom je priložil študijo, ki dokazuje, da se florfenikol razkraja hitro, s časom razkroja DT50 14 ur (izračunanim z Arrheniusovo enačbo za ekstrapolacijo iz DT50 5 ur, merjeno pri 20 °C namesto pri 10 °C, kot priporoča smernica CVMP).
Florfenicol concentrations were below the limit of quantification (LOQ) (0.4 mg/kg) by day 2 and below the limit of detection (LOD) (0.1 mg/kg) by day 27.
Koncentracije florfenikola so bile do 2. dne pod mejo kvantifikacije (0,4 mg/kg), do 27. dne pa pod mejo zaznavnosti (0,1 mg/kg).